Publication
Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel®(MoTOR) phase II trial by the Italian Kidney Cancer Group (GIR)
Michele Milella, Alessandra Felici, Giuseppe Di Lorenzo, Michele Aieta, Raffaele Ardito, Corrado Boni, Ermanno Rondini, Enrico Aitini, Eugenio Villa, Giovanni Lo Re, Renato Algeri, Paolo Foa, Domenico Amoroso, Luca Moscetti, Michele Gallucci, Diana Giannarelli, Sabino De Placido, Francesco Cognetti
April 2012, American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.am2012-lb-226